Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medibuy.com

This article was originally published in The Gray Sheet

Executive Summary

Medical device business-to-business e-commerce firm's initial public offering is anticipated to consist of 13 mil. shares at $10-12 per share, according to an amended registration statement filed March 16 with the Securities and Exchange Commission. The amended prospectus also reflects the March 7 agreement to acquire Premier's medical products e-commerce company Premier Health Exchange (1"The Gray Sheet" March 13, p. 13). The proposed $130-156 mil. offering is about double the $75 mil. offering anticipated in a preliminary prospectus filed in January

You may also be interested in...



Medibuy.com Doubles Registered Buyers Via March 7 Premier Acquisition

Medibuy.com will file an amendment to its S-1 form in the next couple of weeks to reflect the March 7 agreement to acquire Premier's medical products e-commerce company, Premier Health Exchange.

EMA Stands By Suspension Of Ranitidine In EU After Re-Examination

Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.

QUOTED. 22 September 2020. Francis deSouza.

Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel